These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11398906)

  • 21. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
    Ruggenenti P; Perna A; Loriga G; Ganeva M; Ene-Iordache B; Turturro M; Lesti M; Perticucci E; Chakarski IN; Leonardis D; Garini G; Sessa A; Basile C; Alpa M; Scanziani R; Sorba G; Zoccali C; Remuzzi G;
    Lancet; 2005 Mar 12-18; 365(9463):939-46. PubMed ID: 15766995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease.
    Perico N; Ruggenenti P; Remuzzi G
    Curr Opin Pharmacol; 2017 Apr; 33():34-40. PubMed ID: 28482281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The renoprotective effect of antihypertensive drugs.
    Locatelli F; Del Vecchio L; Marai P; Colzani S
    J Nephrol; 1998; 11(6):330-6. PubMed ID: 10048500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition.
    Remuzzi G; Ruggenenti P; Perico N
    Ann Intern Med; 2002 Apr; 136(8):604-15. PubMed ID: 11955029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?
    Laverman GD; de Zeeuw D; Navis G
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):205-13. PubMed ID: 12584664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Boner G
    Isr J Med Sci; 1996 Dec; 32(12):1217-21. PubMed ID: 9007157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic strategy for progressive renal disease].
    Hayashi K; Ozawa Y; Tokuyama H
    Nihon Rinsho; 2001 May; 59(5):955-60. PubMed ID: 11391998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome?
    de Jong PE; Anderson S; de Zeeuw D
    J Am Soc Nephrol; 1993 Jan; 3(7):1333-41. PubMed ID: 8439644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.
    Zaffanello M; Franchini M; Fanos V
    Pharmacotherapy; 2008 Jan; 28(1):125-30. PubMed ID: 18154482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease.
    Shiigai T; Shichiri M
    Am J Kidney Dis; 2001 Mar; 37(3):477-83. PubMed ID: 11228170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
    Ritz E; Orth SR; Strzelczyk P
    J Hypertens Suppl; 1997 Mar; 15(2):S21-6. PubMed ID: 9218194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hypertension in chronic renal insufficiency.
    Locatelli F; Manzoni C; Marcelli D
    J Nephrol; 1997; 10(4):220-3. PubMed ID: 9377731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G; Cao Z; Cooper ME
    Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.